Document:

EX-10.19

 Exhibit 10.19 

VALERITAS HOLDINGS, LLC 

VOTING AGREEMENT 
 This
Voting Agreement (the “Agreement”) is made and entered into as of June 19, 2014, by and among Valeritas Holdings, LLC, a Delaware limited liability company (the “Company”), the holders of the Company’s issued and
outstanding Series A Preferred Units, Series B Preferred Units and Series C Preferred Units (collectively, the “Preferred Units”) listed on Schedule A attached hereto (collectively, the “Investors”), and the holders of the
Company’s issued and outstanding Common Units listed on Schedule B attached hereto (collectively, the “Common Unitholders”). The Company, the Investors and the Common Unitholders are individually referred to herein as a
“Party” and are collectively referred to herein as the “Parties.” The Company’s Board of Managers is referred to herein as the “Board.” Certain other capitalized terms used in this Agreement but not defined where
first used in this Agreement are defined in Section 25 of this Agreement. 
 WITNESSETH: 

WHEREAS, the parties hereto desire to provide for certain matters relating to the Company and the equity securities of the Company that
are from time to time held by the Investors and the Common Unitholders. 
 NOW, THEREFORE, in consideration of the foregoing premises
and certain other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 

1. Agreement to Vote. Each Investor, as a holder of Preferred Units, hereby agrees on behalf of itself and any transferee or assignee
of any such Preferred Units, to hold all of the Preferred Units registered in its name (and any securities of the Company issued with respect to, upon conversion of, or in exchange or substitution of such Preferred Units, and any other voting
securities of the Company subsequently acquired by such Investor) (hereinafter collectively referred to as the “Investor Units”) subject to, and to vote the Investor Units at a regular or special meeting of members (or by written consent)
in accordance with, the provisions of this Agreement. Each Common Unitholder hereby agrees on behalf of itself and any transferee or assignee to hold all of the Common Units and any other securities of the Company acquired by such Common Unitholder
in the future (and any securities of the Company issued with respect to, upon conversion of, or in exchange or substitution for such securities) (the “Common Units”) subject to, and to vote the Common Units at a regular or special meeting
of members (or by written consent) in accordance with, the provisions of this Agreement. 
 2. Board Size. The holders of Investor
Units and Common Units shall vote at a regular or special meeting of members (or by written consent) such securities that they own (or as to which they have voting power) to ensure that the size of the Board shall be set and remain at seven
(7) managers; provided, however, that such Board size may be subsequently increased or decreased pursuant to an amendment of this Agreement in accordance with Section 17 hereof. 

3. Election of Managers; Chairman of the Board. 

(a) In any election of managers of the Company to elect the Series C Managers, the Investors holding Series C Preferred Units shall each vote
at any regular or special meeting of members (or by written consent) such number of Series C Preferred Units then owned by them (or as to which they then have voting power) as may be necessary to elect four (4) managers designated by the

 
holders of a majority of the Series C Preferred Units, which shall initially be Daniel Pelak, Paul Queally, Sean Traynor and John Barr. 

(b) In any election of managers of the Company to elect the Series B Managers, the Investors holding Series B Preferred Units shall each vote
at any regular or special meeting of members (or by written consent) such number of Series B Preferred Units then owned by them (or as to which they then have voting power) as may be necessary to elect three (3) managers in accordance with the
following: (i) one (1) manager nominated by MPM BioVentures IV GP, LLC or its Affiliates, who shall initially be Vaughn Kailian; (ii) one (1) manager nominated by Pitango Venture Capital Fund V, L.P. or its Affiliates, who shall
initially be Ittai Harel; and (iii) one (1) manager nominated by ONSET VI, L.P. or its Affiliates, who shall initially be John Ryan. 

(c) In any election of the Chairman of the Board, the Investors that have nominated a manager to the Board pursuant to subsections 3(a) and
3(b) above shall use their best efforts to cause any manager who has been designated by such Investor in accordance with the terms of this Section 3, at any annual or special meeting of the Board, however called, and in any action by written consent
of the Board, to vote in favor of the election of a Chairman of the Board nominated by the holders of a majority of the Series C Preferred Units, who shall initially be Daniel Pelak (the “Chairman”). 

4. Removal. Any manager of the Company may only be removed from the Board in the manner allowed by Section 3.2(c) of the LLC
Agreement. 
 5. Transfers; Drag-Along Right; Tag-Along Right. 

(a) Transfers. Each Party agrees that it shall not transfer any equity securities of the Company owned by it except as expressly
provided in Sections S(b), (e) and (f). Any transfer or attempted transfer of any such equity securities in violation of any provision of this Agreement shall, to the fullest extent permitted by law, be void ab initio, and the Company shall not
record any such transfer on its books or treat any purported transferee of such equity securities as the owner of such equity securities for any purpose. 

(b) Drag-Along Right. In the event that (i) the Board, including the Board Majority of the Minority and (ii) the Required
Series C Holders approve a Sale of the Company (as defined below), then each holder of Investor Units and Common Units hereby agrees with respect to all securities of the Company which it own(s) or otherwise exercises voting or dispositive
authority: 
 (i) in the event such transaction is to be brought to a vote at a member meeting, after receiving proper
notice of any meeting of members of the Company to vote on the approval of such Sale of the Company, to be present, in person or by proxy, as a holder of voting securities, at all such meetings and be counted for the purposes of determining the
presence of a quorum at such meetings; 
 (ii) to vote (in person, by proxy or by action by written consent, as applicable)
all equity securities of the Company as to which it has beneficial ownership in favor of such Sale of the Company and in opposition of any and all other proposals that could reasonably be expected to delay or impair the ability of the Company to
consummate such Sale of the Company; 
 (iii) to refrain from exercising any dissenters’ rights or rights of appraisal
under applicable law at any time with respect to such Sale of the Company; 

  
 2 

 (iv) to execute and deliver all related documentation and take such other action
in support of or to consummate such Sale of the Company as shall reasonably be requested by the Company; and 
 (v) except
for this Agreement, no holder of Investor Units or Common Units, or any Affiliate thereof, shall deposit any equity securities of the Company beneficially owned by such holder of Investor Units or Common Units, or an Affiliate thereof, in a voting
trust or subject any such equity securities to any arrangement or agreement with respect to the voting of such equity securities. 
 Notwithstanding the
foregoing, no Investor or Common Unitholder shall be required to vote in the manner described by this Section 5(b) unless (i) the net proceeds of such Sale of the Company are to be distributed to members of the Company in accordance with
Section 4.4(b) of the LLC Agreement, (ii) any representation or warranty required to be made by any Investor in connection with such Sale of the Company shall be limited to customary representations and warranties relating to such Investor
and equity securities of the Company owned by such Investor, (iii) the liability for indemnification, if any, of each Investor or Common Unitholder in the Sale of the Company for the inaccuracy of any representation or warranty made by the
Company or applicable Investors and/or Common Unitholders in connection with such Sale of the Company, is several and not joint with any other person or entity (although nothing set forth herein shall be deemed to mean that an escrow fund
established from the proceeds of a Sale of the Company for indemnification of such inaccuracy shall be a violation of the foregoing), is pro rata in proportion to the amount of consideration paid to such Investor or Common Unitholder in connection
with such Sale of the Company and does not exceed the maximum amount of consideration to be received by such Investor or Common Unitholder from the Sale of the Company and (iv) if a choice with regards to the form of consideration is given to
any Investor then all Investors shall be given the same choice. 
 (c) Provisions Applicable to Transfer of Control. Each Investor
agrees that, except as otherwise approved in writing by the holders of a majority of each class of Preferred Units of the Company, such Investor shall not effect or close any transfer, whether in one transaction or a series of related transactions,
to a Person or any Affiliates thereof (other than an underwriter of the Company’s securities or a transferee pursuant to an exempt transfer under Section 5(f)) of the Company’s securities if, after such effectuation or closing, such
Person would hold 50% or more of the outstanding voting securities of the Company (or the surviving or acquiring entity) (any such transaction, a “Control Transfer”) unless (i) the same percentage of units of each class of Preferred
Units of the Company as the percentage of Series C Preferred Units being transferred in such Control Transfer are also transferred in connection with such Control Transfer and (ii) the net aggregate proceeds of such Control Transfer are
distributed to the members of the Company as a Liquidation Event in accordance with Section 4.4(b) of the LLC Agreement. 
 (d)
Additional Drag-Along Right. Each of the Investors holding Series A Preferred Units hereby agrees (a) to vote in person, by proxy or by action by written consent, as applicable, in favor of any amendment to or restatement of the LLC
Agreement, and also in favor of the taking of any other action by the Company or any other resolution of the Company’s members, if such amendment, restatement, action or resolution is approved and/or adopted, as applicable, by the Board
Majority of the Minority and the Required Series C Holders (each such amendment, restatement, action or resolution so approved or adopted, an “Approved Action”) and (b) to take such other actions as are reasonably requested by the
Company to effect and implement any Approved Action; provided that, in each case, such Approved Action would not contravene the voting, approval or waiver rights of the holders of Series A Preferred Units expressly set forth in Sections
3.10(c) of the LLC Agreement. 

  
 3 

 Notwithstanding the foregoing, neither the provisions of this Section 5(d), nor any vote or action taken
pursuant to this Section 5(d) by any person, shall be construed as, or shall otherwise result in, any waiver, estoppel or other limitation of any right or remedy, in law or in equity, of a holder of Series A Preferred Units. 

(e) Tag-Along Rights. Except as provided in Section 5(f), each Investor may transfer equity securities of the Company owned by it,
provided that as a condition of such Proposed Transfer such Investor grants to each other Party a Tag-Along Right with respect to such Proposed Transfer, in which case, the following terms and conditions shall apply: 

(i) Notice. The Investor proposing to make a Proposed Transfer (the “Transferring Holder”) must deliver a
Proposed Transfer Notice to each other Party not later than thirty (30) days prior to the consummation of such Proposed Transfer. 

(ii) Exercise of Right. Each respective Party (except for the Transferring Holder) may elect to exercise its Tag-Along
Right and participate on a pro rata basis (as described in subsection 5(e)(iii)) in such Proposed Transfer on the same terms and conditions specified in the Proposed Transfer Notice. Each Party who desires to exercise its Tag-Along Right (each, a
“Participating Investor”) must give the Transferring Holder written notice to that effect within fifteen (15) days after delivery of the Proposed Transfer Notice, and upon giving such notice such Participating Investor shall be deemed
to have effectively exercised its Tag-Along Right. 
 (iii) Units Includable. Each Participating Investor may
include in the Proposed Transfer all or any part of such Participating Investor’s Investor Units or Common Units equal to the product obtained by multiplying (i) the aggregate number of Transfer Securities subject to the Proposed Transfer
by (ii) a fraction, the numerator of which is the number of Investor Units (on an as converted basis) and Common Units owned by such Participating Investor immediately before consummation of the Proposed Transfer and the denominator of which is
the total number of Investor Units (on an as converted basis) and Common Units outstanding immediately prior to the consummation of the Proposed Transfer. 

(iv) Purchase and Sale Agreement. The Participating Investors and the Transferring Holder agree that the terms and
conditions of any Proposed Transfer will be memorialized in, and governed by, a written purchase and sale agreement with the Prospective Transferee (the “Purchase and Sale Agreement”) with customary terms and provisions for such a
transaction, and the Participating Investors and the Transferring Holder further covenant and agree to enter into such Purchase and Sale Agreement as a condition precedent to any sale or other transfer in accordance with this Section 5(e). The
Purchase and Sale Agreement shall provide that the liability for indemnification by any Prospective Transferee shall not exceed the consideration received by such Prospective Transferee pursuant to the Purchase and Sale Agreement. 

(v) Allocation of Consideration. The aggregate consideration payable to the Participating Investors and the
Transferring Holder shall be allocated based on the number of Transfer Securities sold to the Prospective Transferee by each Participating Investor and the Transferring Holder as provided in paragraph (iii) and shall be allocated to the
Participating Investors and the Transferring Holder in accordance with Section 4.4(b) of the LLC Agreement as if such transfer were a Liquidation Event (as defined in the LLC Agreement). 

  
 4 

 (vi) Purchase by Selling Member; Deliveries. Notwithstanding paragraph
(iv) above, if any Prospective Transferee or Transferees refuse(s) to purchase securities subject to the Tag-Along Right from any Participating Investor or upon the failure to negotiate in good faith a Purchase and Sale Agreement reasonably
satisfactory to the Participating Investors, the Transferring Holder and any Party may not sell any Transfer Securities to such Prospective Transferee or Transferees unless and until, simultaneously with such sale, the Transferring Holder purchases
all securities subject to the Tag-Along Right from such Participating Investor or Investors on the same terms and conditions (including the proposed purchase price) as set forth in the Proposed Transfer Notice and such other terms as such
Participating Investor or Investors and the Transferring Holder shall agree. In connection with such purchase by the Transferring Holder, such Participating Investor or Investors shall deliver to the Transferring Holder a certificate or
certificates, properly endorsed for transfer, representing the securities being purchased by the Transferring Holder. Each such certificate delivered to the Transferring Holder will be transferred to the Prospective Transferee against payment
therefor in consummation of the sale of the Transfer Securities pursuant to the terms and conditions specified in the Proposed Transfer Notice, and the Transferring Holder shall concurrently therewith remit or direct payment to each such
Participating Investor the portion of the aggregate consideration to which each such Participating Investor is entitled by reason of its participation in such sale as provided in this paragraph (vi). 

(vii) Additional Compliance. If any Proposed Transfer is not consummated within one hundred eighty (180) days
after receipt of the Proposed Transfer Notice, the Transferring Holder may not sell any Transfer Securities unless they first comply in full with each provision of this Section 5(e). The exercise or election not to exercise any right by any
Party hereunder shall not adversely affect its right to participate in any other sales of Transfer Securities. 
 (viii)
Violation of Tag-Along If any Transferring Holder purports to sell any Transfer Securities in contravention of the Tag-Along Right (a “Prohibited Transfer”), each Party who desires to exercise its Tag-Along Right may, in addition to
such remedies as may be available by law, in equity or hereunder, require the Transferring Holder to purchase from such Party the type and number of Investor Units or Common Units that such Investor would have been entitled to sell to the
Prospective Transferee had the Prohibited Transfer been effected in compliance with the terms of this Section 5(e). The sale will be made on the same terms and subject to the same conditions as would have applied had the Investor not made the
Prohibited Transfer, except that the sale (including, without limitation, the delivery of the purchase price) must be made within ninety (90) days after the Party learns of the Prohibited Transfer, as opposed to the timeframe proscribed in
paragraph (ii) above. Such Transferring Holder shall also reimburse each Party for any and all reasonable and documented out-of-pocket fees and expenses, including reasonable legal fees and expenses,
incurred pursuant to the exercise or the attempted exercise of the Investor’s Tag-Along Right. 
 (f) Exempt Transfers.
Notwithstanding the foregoing or anything to the contrary herein, the provisions of Sections 5(a), (c) and (e) shall not apply: (i) in the case of a holder of Investor Units and Common Units that is an entity, upon a transfer by such
holder to Affiliates, (ii) to a repurchase of Common Units from a Common Unitholder by the Company at a price no greater than that originally paid by such Common Unitholder for such Common Units and pursuant to an agreement containing vesting
and/or repurchase provisions approved by the Board, (iii) in the case of a Common Unitholder that is a natural person, upon a transfer of Transfer Securities by such Common Unitholder made for bona fide estate planning purposes, either during
his or her lifetime or on death by will or intestacy, to his or her spouse, child (natural or adopted), or any other direct lineal descendant of such Common Unitholder (or his or her spouse) (all of the foregoing collectively referred to as
“Family Members”), or any other relative approved by the Board, or any custodian or trustee of any trust, 

  
 5 

 
partnership or limited liability company for the benefit of, or the ownership interests of which are owned wholly by, such Common Unitholder or any such Family Members, (iv) a transfer of
equity securities of the Company owned by BioValve Technologies, Inc. secured by a promissory note held by Elizabeth Gordon to Elizabeth Gordon or an entity controlled by Elizabeth Gordon, (v) a transfer by Auda Capital IV Co-Investment
GMBH & Co. KG to any entity managed by Auda Capital or Tullis Health, (vi) in the case of a holder of Investor Units, upon a transfer by such holder to another Investor or an Affiliate of such other Investor or (vii) upon a
Proposed Transfer approved by the Board; provided that in the case of clauses (i), (iii), (iv), (v), (vi) and (vii), such Transfer Securities shall at all times remain subject to the terms and restrictions set forth in this Agreement and such
transferee shall, as a condition to such issuance, comply with Section 5.4 of the LLC Agreement and deliver a counterpart signature page to this Agreement as confirmation that such transferee shall be bound by all the terms and conditions of
this Agreement as an Investor or Common Unitholder, as applicable, including the obligations with respect to Proposed Transfers of such Transfer Securities; and provided, further, in the case of any transfer pursuant to clause (iii) above, that
such transfer is made pursuant to a transaction in which there is no consideration actually paid for such transfer. 
 (g) Certain Legal
Requirements. In the event that the consideration to be paid in exchange for Investor Units or Common Units in a Sale of the Company or a Proposed Transfer pursuant to Section 5(b) or Section 5(e) includes any securities, and the receipt
thereof by an Investor or Common Unitholder would require under applicable law (a) the registration or qualification of such securities or of any Person as a broker or dealer or agent with respect to such securities where such registration or
qualification is not otherwise required for the Sale of the Company or the Proposed Transfer or (b) the provision to any Investor or Common Unitholder of any information regarding the Company, such securities or the issuer thereof, including by
reason of the failure of one or more of such holders to be an “accredited investor” as such term is defined in Rule 501 of Regulation D of the Securities Act, such holder(s) shall not have the right to sell its Investor Units or Common
Units in such proposed transaction. In such event, the Company or the Transferring Holder, as applicable, shall have the right, but not the obligation, to cause to be paid to such Investor or Common Unitholder in lieu thereof, against surrender of
its Investor Units or Common Units which would have otherwise been sold in the proposed Sale of the Company or Proposed Transfer, an amount in cash equal to the fair market value of such securities as of the date such securities would have been
issued in exchange for such securities. 
 6. Legend on Unit Certificates. Each certificate, if any, representing any Investor Units
or Common Units shall be endorsed by the Company with a legend reading substantially as follows: 
 “THE UNITS EVIDENCED HEREBY ARE
SUBJECT TO A VOTING AGREEMENT (A COPY OF WHICH MAY BE OBTAINED UPON WRITTEN REQUEST FROM THE ISSUER), AND BY ACCEPTING ANY INTEREST IN SUCH UNITS THE PERSON ACCEPTING SUCH INTEREST SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE
PROVISIONS OF SAID VOTING AGREEMENT.” 
 7. Future Financing. Each Investor and Common Unitholder agrees to vote their Investor
Units and Common Units, as applicable, against any amendment to, or restatement of, the LLC Agreement (and otherwise agrees not to approve, adopt, cause to be executed or cooperate in respect of the execution of any contract) or any equityholder
agreement containing any “pay-to-play” provision or other provision whereby the failure of any Investor to (A) participate in any equity financing or (B) otherwise purchase Company securities would in either case cause (either
alone or in combination with 

  
 6 

 
any other event or condition or set of events and/or conditions) (i) the loss of any rights or preferences associated with the Preferred Units held by such Investor (whether contained in the
LLC Agreement or in any other agreement) or (ii) the automatic conversion to Common Units of any Preferred Units held by such Investor. 

8. Covenant of the Company. The Company will not, by any voluntary action, avoid or seek to avoid the observance or performance of any
of the terms to be performed hereunder by the Company. 
 9. No Liability for Election of Recommended Managers. Neither the Company,
the Investors, the Common Unitholders, nor any officer, director, stockholder, partner, employee or agent of any such Party, makes any representation or warranty as to the fitness or competence of the nominee of any Party hereunder to serve on the
Board by virtue of such Party’s execution of this Agreement or by the act of such Party in voting for such nominee pursuant to this Agreement. 

10. Grant of Proxy. Upon the failure of any Investor or Common Unitholder to vote their Investor Units or Common Units, as applicable,
in accordance with the terms of this Agreement, such Party hereby grants to the Chairman of the Board a proxy coupled with an interest in all Investor Units and Common Units owned by such Party, which proxy shall be irrevocable until this Agreement
terminates pursuant to its terms or this Section 10 is amended to remove such grant of proxy in accordance with Section 17 hereof, to vote all such Investor Units and Common Units in the manner provided in this Agreement. 

11. Specific Enforcement. It is agreed and understood that monetary damages would not adequately compensate an injured Party for the
breach of this Agreement by any other Party, that this Agreement shall be specifically enforceable, and that any breach or threatened breach of this Agreement shall be the proper subject of a temporary or permanent injunction or restraining order.
Further, to the fullest extent permitted by law, each Party hereto waives any claim or defense that there is an adequate remedy at law for such breach or threatened breach. 

12. Execution by the Company. The Company, by its execution in the space provided below, agrees that it will cause the certificates, if
any, issued after the date hereof evidencing the Investor Units and Common Units to bear the legend required by Section 6 hereof, and it shall supply, free of charge, a copy of this Agreement to any holder of a certificate evidencing equity
securities of the Company upon written request from such holder to the Company at its principal office. The parties hereto do hereby agree that the failure to cause the certificates, if any, evidencing the Investor Units and Common Units to bear the
legend required by Section 6 hereof and/or failure of the Company to supply, free of charge, a copy of this Agreement, as provided under this Section 12, shall not affect the validity or enforcement of this Agreement. 

13. Captions. The captions, headings and arrangements used in this Agreement are for convenience only and do not in any way limit or
amplify the terms and provisions hereof. 
 14. Notices. All notices and other communications given or made pursuant hereto shall be
in writing and shall be deemed effectively given or delivered: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed facsimile if sent during normal business hours of the recipient; if not, then on the next
business day, (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying
next day delivery, with written verification of receipt. All 

  
 7 

 
communications shall be sent to the respective parties at the addresses set forth on the signature pages attached hereto (or at such other addresses as shall be specified by notice given in
accordance with this Section 14). 
 15. Term. This Agreement shall terminate and be of no further force or effect upon a Holdco
Liquidation. 
 16. Manner of Voting. The voting of securities pursuant to this Agreement may be effected in person, by proxy, by
written consent or in any other manner permitted by applicable law. 
 17. Amendments and Waivers. Any term hereof may be amended and
the observance of any term hereof may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of (i) the Company, (ii) the Required Series C Holders and
(iii) the Required Series B Holders; provided, however, that in the event that such amendment or waiver adversely affects the rights of (a) the Common Unitholders, in their capacity as such, in a different manner than Investors
holding outstanding Preferred Units, if any, in their capacities as such, such amendment or waiver shall also require the written consent of the holders of a majority of the then outstanding Common Units or (b) the Investors holding Series A
Preferred Units, in their capacity as such, in a different manner than the Investors holding outstanding Series B Preferred Units or Series C Preferred Units, if any, in their capacities as such, such amendment or waiver shall also require the
written consent of the Required Series A Holders; provided, further that a new member of the Company shall become a party to this Agreement without the necessity of an amendment if the acquisition of securities of the Company is made in
accordance with the terms and conditions of this Agreement (including the execution of a counterpart to this Agreement by such new member to be bound hereby). Any amendment or waiver so effected shall be binding upon all the Parties hereto.
Notwithstanding the foregoing (other than with respect to the last sentence of this Section 17), this Agreement may be amended without the consent of the Required Series B Holders in connection with the issuance of equity securities of the
Company in a third party led financing, the issuance of which does not require the approval of any holder of Series B Preferred Units pursuant to Section 3.1O(b) of the LLC Agreement; provided that such amendment does not adversely affect the
rights of the holders of Series B Preferred Units, in their capacity as such, in a different manner than the holders of Series C Preferred Units, in their capacities as such. Notwithstanding the foregoing, Section 5 may not be amended without
the consent of the WCAS Investors and Section 7 may not be amended without the written consent of holders of a majority of each series of Preferred Units impacted by the proposed pay to play provision. 

18. Unit Splits, Unit Dividends, etc. In the event of any issuance of the Company’s voting securities hereafter to any of the
Parties hereto (including, without limitation, in connection with any unit split, unit dividend, recapitalization, reorganization or the like), such securities shall become subject to this Agreement and, to the extent such securities are
certificated, shall be endorsed with the legend set forth in Section 6. 
 19. Severability. Whenever possible, each provision
of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision shall be ineffective
only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. 

  
 8 

 20. Additional Parties. 

 
 (a) In the event that after the date of this Agreement, the Company
enters into an agreement with any person to issue equity securities to such person to someone that is not a party hereto, then the Company shall cause such person, as a condition to entering into such agreement, to become a party to this Agreement
as a Common Unitholder, in the case of the issuance of Common Units, and an Investor, in the case of Preferred Units, by executing and delivering the Adoption Agreement attached to this Agreement as Exhibit A. 

(b) Schedule A and B hereto may be amended by the Company from time to time without the consent of the other parties hereto to add
information regarding Investors and Common Unitholders that become a party to this Agreement pursuant Section 20(a) above. 
 21.
Binding Effect. In addition to any restriction on transfer that may be imposed by any other agreement by which any Party hereto may be bound, this Agreement shall be binding upon the Parties, their respective heirs, successors, transferees
and assigns and to such additional individuals or entities that may become members of the Company and that desire to become Parties hereto; provided that for any such transfer to be deemed effective, the transferee shall have executed and delivered
an Adoption Agreement substantially in the form attached hereto as Exhibit A. Upon the execution and delivery of an Adoption Agreement by a transferee reasonably acceptable to the Company, such transferee shall be deemed to be a Party hereto
as if such transferee’s signature appeared on the signature pages hereto. By its execution hereof or any Adoption Agreement, each of the Parties hereto appoints the Company as its attorney-in-fact for the purpose of executing any Adoption
Agreement which may be required to be delivered hereunder. 
 22. Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware, without regard to conflicts of law principles thereof. 
 23. Entire Agreement.
This Agreement is intended to be the sole agreement of the Parties as it relates to the subject matter hereof and supersede all other agreements of the Parties relating to the subject matter hereof. 

24. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. 
 25. Certain Other Definitions. In addition the terms defined
elsewhere in this Agreement, the following terms shall have the definitions set forth below for the purposes of this Agreement: 
 (a)
“Affiliate” means any Person who, directly or indirectly, controls, is controlled by or is under common control with another Person, including, without limitation, any general partner, managing member, officer or director of such Person or
any venture capital or private equity fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person. For all purposes hereunder, (i) Kaiser
Permanente Ventures LLC—Series A, Kaiser Permanente Ventures LLC—Series B and The Permanente Federation LLC shall be deemed to be Affiliates of each other and (ii) any entity managed by Auda Capital or Tullis Health shall be deemed to
be an Affiliate of Auda Capital IV Co-Investment GMBH & Co. KG. 

  
 9 

 (b) “Board Majority of the Minority” means the affirmative vote of a majority of the
managers consisting of the Series B Managers. 
 (c) “Holdco Liquidation” means such time as the Company distributes all of its
equity securities of Valeritas, Inc. to its members pursuant to Section 4.4(b) of the LLC Agreement. 
 (d) “LLC Agreement”
means the Amended and Restated Limited Liability Company Agreement of the Company, dated on or about the date hereof, as the same may be amended, restated, modified or supplemented from time to time in accordance with its terms. For the avoidance of
doubt, this Agreement constitutes part of the limited liability agreement (as such term is defined in the Delaware Limited Liability Company Act) of the Company. 

(e) “Person” means an individual, firm, corporation, partnership, association, limited liability company, trust or any other
entity. 
 (f) “Proposed Transfer” means any assignment, sale, offer to sell, pledge, mortgage, hypothecation, encumbrance,
disposition of or any other like transfer or encumbering of any Transfer Securities (or any interest therein) proposed by any Investor or Common Unitholder. 

(g) “Proposed Transfer Notice” means written notice from the applicable Investor setting forth the terms and conditions of a
Proposed Transfer. 
 (h) “Prospective Transferee” means any person to whom the applicable Investor proposes to make a Proposed
Transfer. 
 (i) “Required Series A Holders” means the members of the Company who are holders of at least sixty percent
(60%) of the outstanding Series A Preferred Units held by members, voting together as a separate class on an as converted basis. 

(j) “Required Series B Holders” means the members of the Company who are holders of a majority of the outstanding Series B
Preferred Units held by members, voting together as a separate class on an as converted basis. 
 (k) “Required Series C Holders”
means the members of the Company who are holders of a majority of the then outstanding Series C Preferred Units held by members, voting together as a separate class on an as converted basis. 

(1) “Sale of the Company” means a transaction that qualifies as a “Liquidation Event” as defined in the LLC Agreement.

 (m) “Series B Managers” has the meaning ascribed to such term in the LLC Agreement. 

(n) “Series C Managers” has the meaning ascribed to such term in the LLC Agreement. 

(o) “Tag-Along Right” means the right, but not an obligation, of a Party to participate in a Proposed Transfer to a Proposed
Transferee on the terms and conditions specified in the Proposed Transfer Notice. 

  
 10 

 (p) “Transfer Securities” means the Investor Units and/or Common Units held by an
Investor or Common Unitholder, as applicable. 
 (q) “WCAS Investors” means Welsh, Carson, Anderson & Stowe XI, L.P. and
any person or entity that is a shareholder, member, manager, general partner, limited partner, employee or Affiliate of Welsh, Carson, Anderson & Stowe XI, L.P. 
  

[Signature Page Follows] 

  
 11 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first
above written. 
  

			
	 COMPANY:
  

VALERITAS HOLDINGS, LLC

		
	By:	 	/s/ Kristine Peterson
	 Name:
 Title:

Address:
	 	 Kristine Peterson
 CEO

75 Route 202 South, Suite 600
 Bridgewater, NJ 08807

 SCHEDULE A 

INVESTORS 
 WCAS Capital Partners IV, L.P.

 WCAS Management Corporation 
 WCAS Valeritas Holdings, LLC

 WCAS XI Co-Investors, LLC 
 MPM BioVentures IV-QP, L.P.

 MPM BioVentures IV GmbH & Co. Beteiligungs KG 

MPM Asset Management Investors BV4 LLC 
 ONSET VI, L.P. 

Pitango Venture Capital Fund V, L.P. 
 Pitango Venture Capital
Principals Fund V, L.P. 
 U.S. Venture Partners IX, L.P. 

U.S. Venture Partners X, L.P. 
 USVP X Affiliates, L.P. 

Auda Capital IV Co-Investment GMBH & Co. KG 
 Auda
Capital IV Co-Investment Fund, L.P. 
 Auda Valeritas Segregated Portfolio 

PED-VLRTS, LLC 
 Abingworth BioVentures V LP 

Advanced Technology Ventures VIII, L.P. 
 HLM Venture Partners
II, L.P. 
 Tullis Opportunity Fund, L.P. 
 Tullis Opportunity
Fund II, L.P. 

  
 S-1 

 Agate Medical Investments LP 

Agate Medical Investments (Cayman) LP 
 I.I.Y Mordechay Ltd.

 Saint John’s University 
 The Permanente Federation
LLC - Series I 
 Kaiser Permanente Ventures, LLC – Series A 

Kaiser Permanente Ventures, LLC – Series B 
 CHL Medical
Partners III, LP 
 CHL Medical Partners III Side Fund, LP 

The Board of Trustees of the Leland Stanford Junior University (DAPER I) 

The Board of Trustees of the Leland Stanford Junior University (SBST) 

Evan Norton 
 Highbridge International LLC 

South Ferry #2, LP 
 Meyers Family Revocable Trust 

Brian W. Beutel 
 John Curtin 

Joe Fitzgerald 
 John E. and Betty Davis 

Kenneth L. and Grace L. Franke Living Trust 
 Elizabeth Gordon

  
 S-2 

 SCHEDULE B 

COMMON UNITHOLDERS 
 Elizabeth Gordon 

Kathy Aycok 
 Mandy Bentley 

Joseph Brown 
 Michele Carter 

Dan Connors 
 Yash Dave 

Arleen DeCicco 
 Timothy E. Last 

Steven F. Levesque 
 Glenda Lewis 

Ronald Manning 
 Massachusetts Development Finance Agency 

Devin V. McAllister 
 Lisa J. McGuinness 

Heather Merolli 
 Deborah J. Nagy 

Hung Nguyen 
 Michael Price 

William Rebello 
 Tam Pham 

Greg Sellman 
 Mike Stout 

Poul Strange 
 Christine Tanaka 

Oscar Tamayo 
 Mark D. Taylor 

The Estate of Frank Baldino, Jr. 
 The Helen L. Levesque 2012
Trust, Helen L. Levesque, Trustee 

  
 S-3 

 EXHIBIT A 

ADOPTION AGREEMENT 

This Adoption Agreement (“Adoption Agreement”) is executed by the undersigned (“Transferee”) pursuant to the terms of that
certain Voting Agreement dated as of June 19, 2014 (as the same may be amended, restated, modified or supplemented from time to time in accordance with its terms, the “Agreement”) by and among the Company and certain of its members.
Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Adoption Agreement, the Transferee agrees as follows: 

(a) Acknowledgment. Transferee acknowledges that Transferee is acquiring certain equity securities of the Company (the
“Securities”), subject to the terms and conditions of the Agreement. 
 (b) Agreement. Transferee (i) agrees that the
Securities acquired by Transferee shall be bound by and subject to the terms of the Agreement, (ii) shall be deemed an [Investor] [Common Unitholder] for all purposes under the Agreement and (iii) hereby adopts the Agreement with the same
force and effect as if Transferee were originally a Party thereto. 
 (c) Notice. Any notice required or permitted by the Agreement shall be
given to Transferee at the address listed beside Transferee’s signature below. 
 EXECUTED AND DATED this
     day of             , 201    . 
  

					
	TRANSFEREE:
		
	By:	 	  

		 	Name and Title

 
			
		
	Address:	 	  

 
			
	Fax:	 	  

  

			
	Accepted and Agreed:
	
	VALERITAS HOLDINGS, LLC
		
	By:	 	  

		
	Title:Ex 10.10 - 2014 10K Brightwell Contract

THIS AGREEMENT is made 31 December 2014

		
	(1)
	COCA-COLA ENTERPRISES LIMITED (registered in England No. 27173) whose registered office is at Enterprises House, Uxbridge, Middlesex UB8 1EZ ("the Company")

and

(2)    Laura Brightwell
 ("You")

WHEREBY IT IS AGREED as follows:-

1.    Term of Appointment

		
	(A)
	You shall serve the Company as SVP, Public Affairs and Communications, or in such other capacity of a like status as the Company may reasonably require with effect from the Commencement Date or such other date as may be agreed in writing, unless and until your employment shall be terminated by the Company giving to you not less than six months’ notice in writing or you giving to the Company not less than six months’ notice in writing in either case expiring at any time.

		
	(B)
	If either you or the Company have given notice of termination of employment to the other, instead of requiring you to work during your notice period (or any remaining part of it), the Company may (at its discretion) choose to terminate your employment immediately and pay you a sum equivalent to your basic salary only (less appropriate income tax and National Insurance deductions) in lieu of your outstanding contractual notice period.  The Company may elect at its discretion to make any such payment as one lump sum or in equal instalments on the days when you would have received your basic salary if you had continued in employment throughout your notice period.

. 
		
	(C)
	The Company reserves the right to change (including upwards or downwards) the grading attributed to your role at any time.

		
	(D) 
	Your previous employment with the Company counts as part of your continuous employment with the Company. Your continuous employment with the Company therefore commenced on 12th November 1990.

2.    Powers and Duties

		
	(A)
	You shall exercise such powers and perform such duties consistent with your status in relation to the business of the Company or any Associated Company as may from time to time be assigned to you by the Company. You shall comply with all directions from the Company and whatever codes, policies, procedures and rules that the Company may introduce which may apply to your employment. You shall report to the Chairman & Chief Executive Officer or whichever person is nominated by the Company at any time.  The Company may change your reporting line at any time or insert additional tiers of management above you.

(B)    You must:

(i)    promote and protect the interests and reputation of the Company and its
Associated Companies;

(ii)    perform your duties in a professional and co-operative manner;

		
	(iii)
	promptly disclose to the Company any information which comes into your possession which may materially adversely affect the Company, including any information about another employee’s plans to resign and/or compete with the Company;

		
	(iv)
	promptly disclose to the Board any material breach by the Company of any legal obligation, any material financial mismanagement or any other malpractice within the Company which comes to your attention;

		
	(v)
	keep the Company fully informed of your business-related activities and give whatever information and explanations are requested of you by the Company;

		
	(vi)
	conduct your personal and working life in a way that does not damage or risk damaging your own or the Company’s reputation;  and

		
	(vii)
	comply with all Company policies and procedures including, without limitation, the Company’s Code of Business Conduct.

		
	(C)
	You shall travel to such places as the Company may from time to time reasonably require.

		
	(D)
	Your normal place of work shall be the Company’s offices at Uxbridge.  However, the Company reserves the right to change this location to any other location within the United Kingdom or worldwide.

3.    Salary

		
	(A)
	You shall be paid an annual salary of £190,000 which is paid in arrears at four weekly intervals.

		
	(B)
	The Company shall review, but shall not be obliged to increase, the salary payable under this Agreement each year.

		
	(C)
	The Company reserves the right to deduct from you salary or any other sums due to you any payments due from you to the Company.

4.    Pensions

(A)    You are entitled to be a member of the Pension Plan subject to the rules of the Pension
Plan.  Changes in the rules of the Pension Plan will be notified to you in writing. Your contributions to the Pension Plan will be deducted from your salary.

(B)    A contracting out certificate is in force in respect of your employment under this
Agreement.

5.    Car

The Company shall provide for you (subject to you being qualified to drive) a car or alternatively a cash allowance in accordance with its Car Policy in place at the time. You shall abide by the terms of this policy, take good care of the car, procure that the provisions of any policy of insurance are observed and return the car, clean and in good repair to the Company's registered office immediately upon the termination of your employment.

6.    Sickness

Subject to compliance with the Company’s Attendance Management Policy and the Sick Leave guidance as published on the CCE Intranet, you will be eligible to receive sick pay in line with Company policy in operation at that time inclusive of any Statutory Sick Pay payable to you.

7.    Other Benefits

The following benefits currently apply to you.  The Company, however, reserves the right to withdraw, alter or replace any of these benefits. In such circumstances, there shall be no obligation on the Company to replace any benefit with an equivalent or indeed any other benefit.

(A)    Management Incentive Plan

You shall be eligible to participate in the Coca-Cola Enterprises Inc. Management
Incentive Plan, subject to the rules of such Plan.

(B)    Long-Term Incentive Plan

You shall be eligible to participate in the Coca-Cola Enterprises Inc. Long-Term Incentive Plan.  All grants of awards under the scheme are made at the sole discretion of the Board of Directors of Coca-Cola Enterprises Inc.

(C)    Share Plan

You shall be eligible, at the Company’s discretion, to participate in the CCE UK Share Plan, subject to the rules of such Plan.

(D)    Healthcare

The Company will cover you and your family (spouse and dependent children) under a private medical insurance scheme, subject to the rules and terms and conditions of
such scheme.

(E)    Health Assessments

You are entitled to regular medicals in accordance with the provisions published on the CCE Intranet.

(F)    Accident Insurance

The Company will provide you with 24 hour worldwide accident cover in accordance with Company policy in operation at that time, subject to the rules and terms and conditions of such cover.

(G)    Life Assurance

If you are, or choose to become, a contributing member of the CCE Pension Plan, the Company will provide you with death in service cover equal to four times basic salary subject to the rules and terms and conditions of such cover. However, if you decline to join the Pension Plan, the life assurance cover will be equal to one times gross earnings in the 12 months before death.

(H)    Options Benefit

You will be entitled to benefit from the Company’s Options Flexible Benefit Scheme, subject to the rules of such Scheme.

(I)    Financial Planning and Advice

Following your localisation to the UK and as from the commencement of 2015 tax year, the Company will provide tax preparation services for you through 2017  It is your responsibility to ensure that you disclose the value of this taxable benefit to HMRC so that they can include this in the valuation of your benefit in kind taxation.

		
	8.
	Expenses

The Company shall reimburse to you out-of-pocket expenses which you may from time to time incur in the proper performance of your duties under this Agreement subject to the rules of its Travel and Expenses Policy from time to time in force.

		
	9.
	Holidays

		
	(A)
	Your annual holiday entitlement is 27 days plus 8 public holidays (pro rata in the first year of employment).

		
	(B)
	The holiday year runs from 1 January to the following 31 December and holiday must be taken during that period at times agreed with your superior.

		
	(C)
	On leaving the Company you will be paid salary equivalent to unused accrued holiday entitlement or required to repay any holiday in excess of your accrued entitlement in either case, at the daily rate of 1/260 of your basic annual salary.

10.    Intellectual Property

		
	(A)
	It shall be part of your normal duties at all times:

		
	(i)
	to consider in what manner and by what new methods or devices the products, services, processes, equipment or systems of the Company, or any Associated Company, with which you are concerned or for which you are responsible might be improved;

		
	(ii)
	promptly to give to the Secretary of the Company full details of any invention or improvement which you may from time to time make or discover in the course of your duties: and

		
	(iii)
	to further the interests of the Company's undertaking.  Subject to the Patents Act 1971, the Company shall be entitled free of charge to the sole ownership of any such invention or improvement and to its exclusive use.

		
	(B)
	You shall immediately, both during your employment and afterwards. at the request and cost of the Company apply for and execute and do all such documents, acts and things as may in the opinion of the Company be necessary or conducive to obtain letters patent or other protection for any such invention or improvement in any part of the world and to vest such letters patent or other protection in the Company or its nominees.

		
	(C)
	You acknowledge and agree that any work created or developed by you (whether alone or jointly) during your employment by the Company will belong to the Company if it:

		
	(i)
	is capable of exploitation by the Company in the normal course of its business;

or

		
	(ii)
	is so created or developed during the course of or in connection with your employment by the Company.

4

To the extent that they do not vest automatically, you assign to the Company all copyright, design rights and other intellectual property rights in any such work and undertake to do anything reasonably required to ensure that such rights belong to or are assigned to the Company and to assist the Company in protecting or maintaining them.

		
	(D)
	You hereby irrevocably authorise the Company for the purposes of the intellectual property provisions of this Agreement to make use of your name and to sign and to execute any documents or do any thing on your behalf (or where permissible to obtain the patent or other protection in its own name or in that of its nominees).

		
	(E)
	You shall not knowingly do anything to imperil the validity of any patent or protection or any application of the patent but shall at the cost of the Company render all possible assistance to the Company, or any Associated Company, both in obtaining and in maintaining such patent or other protection.

		
	(F)
	You shall not either during your employment or afterwards exploit or assist others to exploit any invention or improvement which you may from time to time make or discover in the course of your duties or (unless the same shall have become public knowledge) make public or disclose any such invention or improvement or give any information in respect of it except to the Company or as it may direct.

		
	11.
	Confidential Information

Except for information which is in the public domain (save as a result of your breach of confidence) or which you are required to disclose by law or regulation, you shall not, either during your employment or afterwards, use to the detriment or prejudice of the Company or any Associated Company or, except in the proper course of your duties during this Agreement, divulge to any person any trade secret or any other Confidential Information which may have come to your knowledge during your employment.

		
	12.
	Post-termination Restrictions

		
	(A)
	In order to protect the Company’s confidential information, trade secrets, goodwill customer base, potential customer base, other business connections and stable workforce, you agree to be bound by the restrictions set out below.

You will not Directly or Indirectly without the Company’s written consent:

		
	(i)
	for the period of six months following the Termination Date be engaged in or concerned in any executive, technical or advisory capacity in any business concern which is in competition with the business of the Company or any Relevant Associated Company.  This restriction shall not restrain you from being engaged or concerned in any business concern in so far as your duties or work shall relate solely:

		
	(a)
	to geographical areas where the business concern is not in competition with the Company or any Relevant Associated Company; or

5

		
	(b)
	to services or activities of a kind with which you were not concerned to a material extent during employment with the Company.

		
	(B)
	The parties to this Agreement agree that each of the clauses of this Agreement is separate and severable and enforceable accordingly and if any of the clauses shall be adjudged to be void or ineffective for whatever reason but would be adjudged to be valid and effective if part of the wording therefore was deleted, they shall apply such modifications as may be necessary to make them valid and effective.

		
	(C)
	Any period of restriction set out above will be reduced by one day for every day during the notice period which the Company required you both to remain away from its premises and not to carry out your normal duties.

		
	13.
	Restrictions During Employment

		
	(A)
	During your employment you shall not (unless otherwise agreed in writing by the Company) undertake any other business or profession or be or become an employee or agent of any other company, firm or person or assist or have any financial interest in any other financial interest in any other business or profession.  You may, however, hold or acquire by way of bona fide investment only up to 3% of the issued shares of any company listed on any recognised investment exchange for the purpose of investment only, where recognised investment exchange has the meaning given in section 285 of the Financial Services and Markets Act 2000.  You may invest in shares or other securities which are not listed or dealt in on any recognised stock exchange with the prior agreement of the Company.

		
	14.
	Garden leave

		
	(A)
	The Company reserves the right at any time during any period of notice to require you:

		
	(i)
	to remain away from the Company’s premises;

		
	(ii)
	to work from home;

		
	(iii)
	to carry out special projects outside the normal scope of your duties;

		
	(iv)
	not to carry out some of your normal duties; and/or

		
	 (v)
	not to carry out any of your normal duties; and the Company may appoint another person to carry out any of your duties at such times.

		
	(B)
	If the Company exercises this right, you will receive your basic salary and all benefits to which you are entitled and you must:

		
	(i)
	continue to comply with your implied duties, including those of good faith and fidelity; and

		
	(ii)
	continue to comply with the express duties set out in this Agreement, except those from which you are explicitly released by the Company.

6

		
	15.
	Return of Property

		
	(A)
	You shall promptly whenever requested by the Company and in any event upon the termination of your employment deliver to the Company all lists of customers, correspondence and all other documents, papers and records which may have been prepared by you or have come into your possession or control in the course of your employment, and you shall not be entitled to retain any copies of such property.

		
	(B)
	You must delete any documents relating to the Company’s business on any personal computer in your control or possession after having forwarded copies to the Company. You must permit the Company both during and after the termination of your employment access to any computer which you have used in relation to the Company’s business.  You must inform the Company of any computer passwords reasonably required by the Company.

16.    Termination of Employment

		
	(A)
	The Company shall be entitled by notice in writing to you to terminate your employment under this Agreement with immediate effect (without a payment in lieu of notice) if you:

		
	(i)
	materially damage or risk materially damaging your or the Company’s reputation;

		
	(ii)
	shall be guilty of serious misconduct or shall have committed any serious breach or repeated or continued (after warning in writing and having refused or failed to remedy accordingly within a reasonable time) any other breach of your obligations under this Agreement.

		
	(B)
	Any delay by the Company in exercising any right of termination shall not constitute a waiver of it.

		
	17.
	Disciplinary and Grievances

		
	(A)
	If you have a grievance relating to your employment, you should raise this in accordance with the Company’s Grievance Procedure.

		
	(B)
	The Company has a Disciplinary and Performance Management Procedure.  This is a policy document designed to apply where a disciplinary or performance management issue arises.

		
	(C)
	The Company may suspend you for however long it considers appropriate in order to investigate any aspect of your performance or conduct or to follow disciplinary proceedings.  The Company may attach conditions to any such suspension and you must comply with any such conditions and co-operate fully with any investigation. During any period of suspension, you would normally receive the same pay and benefits as if you were at work.

		
	18.
	Termination Payment

7

In the event that the Company terminates your employment other than pursuant to clause 16(A) above, you shall be entitled to a termination payment equivalent to the sum of your annual basic salary at the Termination Date and your then on-target annual bonus, provided that you release (in writing) the Company and its Associated Companies from any legal claims related to your employment and/or your termination.  Notwithstanding the foregoing, in the event the Company terminates your employment (other than pursuant to clause 16(A) above), or you voluntarily terminate your employment for Good Reason, within 24 months of a Change in Control of Coca-Cola Enterprises, Inc., you shall be entitled to a termination payment equivalent to the sum of 1.5 times your annual basic salary at the Termination Date and 1.5 times your then on-target bonus, provided you release (in writing) the Company and its Associated Companies from any legal claims related to your employment and/or your termination.  Any termination payment made under this clause 18 shall be inclusive of any payment in lieu of notice or any payment in respect of any period of garden leave, or, in the event of your redundancy, under the Company’s redundancy policy, and such payment shall be made within 45 days of the later of your Termination Date or the date on which the release is fully executed by all parties.

For purposes of this clause 18, “Good Reason” means Employee’s (i) material diminution of duties, responsibilities and status; (ii) material reduction in both base salary and annual incentive opportunities (except for reductions in annual incentive opportunities due to individual performance adjustments); or (iii) assignment to a position requiring relocation of more than 50 miles from the Employee’s primary workplace, unless she voluntarily consents to the applicable change in clause (i), (ii), or (iii).  Employee must give written notice to the Company within 60 days of the date on which she is notified of such circumstances, and the Company will have 30 days to remedy the matter.
		
	19.
	Repayment of Incentive Compensation

Employee agrees that she is subject to the Coca-Cola Enterprises, Inc. Policy on Forfeiture and Repayment of Incentive and Other Compensation, as adopted by the Human Resources and Compensation Committee of the Board of Coca-Cola Enterprises on December 16, 2014.    
20.    Other Agreements

		
	(A)
	This Agreement replaces all previous terms and conditions governing your employment with the Company or any Associated Company , except. the Letter of Assignment between you and Coca-Cola Enterprises, Inc., governing the terms of your relocation, which shall continue in effect according to its terms.

		
	(B)
	You acknowledge that there are no agreements or arrangements whether written, oral or implied between the Company or any Associated Company and you relating to your employment other than those expressly set out in this Agreement and thoseagreements referenced in Section 18(A), and that you have not entered into this Agreement in reliance on any representation not expressly referred to in this Agreement.

		
	(C)
	There are no collective agreements which affect your terms and conditions.

8

		
	21.
	Governing Law

This Agreement shall be governed by and construed under the laws of England and Wales and of the Courts of England and Wales are to have non-exclusive jurisdiction to settle any disputes which may arise out of or in connection with this Agreement.

22.    Definitions

In this Agreement:

	
				
	“Associated Company”
	means a company, which is from time to time a subsidiary or a holding company of the Company or a subsidiary (other than the Company) of a holding company of  the  Company. In this definition "subsidiary" and "holding company" have the same meanings as in Section 736 of the Companies Act 1985 as originally enacted.

	“Change in Control”

“the Commencement Date”
	 shall have the same meaning as in the Coca-Cola Enterprises,   Inc. Incentive Award Plan, as it may be amended from time to time.

means 30th  December 2014

	 
	 
	 

	

“Confidential Information”
	

means any confidential information, including but not limited to:

	 
	 
	a. lists of the Company’s actual or potential customers;

b. details of relationships or arrangements with or knowledge of the requirements of the Company’s actual or potential customers;

c. details of the Company’s business methods, finances, prices or pricing  strategy, marketing or development plans or strategies;

d. personal information about any of the Company’s directors or employees;

e. information divulged to the Company by a third party in confidence; and

f. any information relating to the Company or any of its customers or suppliers which the Company or customer or supplier in question reasonably considers to be confidential.

Confidential Information does not include information which is generally known or easily accessible by the public, unless it is generally known or easily accessible by the public because of a breach of your obligations.

9

	
				
	

“Customer”
	

means any Person who at any time during the period of 12 months immediately before the Termination Date was a customer of the Company or any Associated Company:

a. with whom you had material dealings or for whom you had responsibility on behalf of the Company or any Associated Company at any time during that period; or

b. in respect of whom you obtained or otherwise received Confidential Information.

	

“Directly or Indirectly”
	

means directly or indirectly on either your own account or in conjunction with or on behalf of any other Person.

	

“Key Person”
	

means any individual:

a.  who at any time during the period of 6 months immediately before the Termination Date was 

10

	
		
	b. with whom you worked to a material extent or for whom you had managerial responsibility at any time during that period; and

c. who was employed or engaged in a senior, financial,  research,  technical,  managerial, sales, professional or equivalent capacity.

	

“Person”
	

means  individual,  firm,  company,  association, corporation or other organisation

	

“Prospective Customer”
	

means any Person who at any time during the period of 6 months immediately before the Termination Date had Relevant Discussions in which  you  were materially involved,  for which you   had   responsibility   or   about   which   you obtained or otherwise received Confidential Information.

	

“Relevant Associated
Company”
	

means an Associated Company with which you have  dealt  or  for  which  you  have  had responsibility during your employment by the Company.

	

“Relevant Discussions”
	

means any discussion, pitch, tender, presentation or  negotiation  with  the  Company  or  any Associated Company with a view to receiving products or services from the Company or any Associated Company.

	

“Restrictive Products or
Services”
	

means any products or services which compete with or are of the same or similar kind as any products or services:

a. provided by the Company or any Associated Company in the ordinary course of its business during the period of 12 months immediately before the Termination Date; and

b. in   respect   of   which   you   were   directly concerned, were materially involved or had responsibility during your employment by the Company or any Associated Company; or

c. about   which   you   obtained   or   otherwise received   Confidential Information.

		
	“Termination Date”
	means the date of termination of your employment with the Company.

		
	“the Pension Plan”
	means the CCE Personal Pension Plan.

Signed on behalf of Coca-Cola Enterprises

11

By:/s/ Frank Govaerts    12/31/2014_
Director    DATE

/s/ Laura Brightwell    12/31/2014______
		
	Laura Brightwell 
	DATE

12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}]]